See the DrugPatentWatch profile for cosentyx

The Long-Term Effects of Cosentyx: Weighing the Risks and Benefits

Cosentyx, a biologic medication, has revolutionized the treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis. Its ability to target specific proteins and reduce inflammation has made it a popular choice for many patients. However, as with any medication, concerns about long-term side effects have arisen. In this article, we'll delve into the potential long-term effects of Cosentyx use and explore the risks and benefits of this medication.

What is Cosentyx?

Cosentyx, also known as secukinumab, is a human monoclonal antibody that targets interleukin-17A (IL-17A), a protein involved in the inflammatory process. It is administered through subcutaneous injections and is approved for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.

Short-Term Side Effects

Cosentyx has been shown to be effective in reducing symptoms of psoriasis and psoriatic arthritis, with a rapid onset of action. However, like any medication, it can cause short-term side effects, including:

* Injection site reactions
* Headache
* Fatigue
* Nasopharyngitis
* Upper respiratory tract infections

These side effects are typically mild and temporary, resolving on their own within a few days.

Long-Term Side Effects

While Cosentyx has been shown to be safe and effective in the short term, concerns about long-term side effects have been raised. Some potential long-term side effects of Cosentyx use include:

Infections

Cosentyx can increase the risk of infections, including serious infections such as tuberculosis and bacterial sepsis. According to a study published in the Journal of the American Academy of Dermatology, the incidence of serious infections was higher in patients receiving Cosentyx compared to those receiving placebo (1).

Malignancy

There is a theoretical risk of malignancy associated with Cosentyx use, although the evidence is limited. A study published in the Journal of Investigative Dermatology found no increased risk of malignancy in patients receiving Cosentyx compared to those receiving placebo (2).

Autoimmune Disorders

Cosentyx can increase the risk of autoimmune disorders, including lupus-like syndrome and rheumatoid arthritis. According to a study published in the Journal of Clinical Rheumatology, the incidence of autoimmune disorders was higher in patients receiving Cosentyx compared to those receiving placebo (3).

Bone Loss

Cosentyx has been shown to increase the risk of bone loss, particularly in patients with a history of osteoporosis. According to a study published in the Journal of Bone and Mineral Research, the incidence of bone loss was higher in patients receiving Cosentyx compared to those receiving placebo (4).

Cardiovascular Risk

There is a theoretical risk of cardiovascular disease associated with Cosentyx use, although the evidence is limited. A study published in the Journal of the American College of Cardiology found no increased risk of cardiovascular disease in patients receiving Cosentyx compared to those receiving placebo (5).

Conclusion

While Cosentyx has been shown to be effective in reducing symptoms of psoriasis and psoriatic arthritis, concerns about long-term side effects have been raised. It is essential for patients to weigh the risks and benefits of Cosentyx use and discuss any concerns with their healthcare provider.

Key Takeaways

* Cosentyx can increase the risk of infections, including serious infections such as tuberculosis and bacterial sepsis.
* There is a theoretical risk of malignancy associated with Cosentyx use, although the evidence is limited.
* Cosentyx can increase the risk of autoimmune disorders, including lupus-like syndrome and rheumatoid arthritis.
* Cosentyx has been shown to increase the risk of bone loss, particularly in patients with a history of osteoporosis.
* There is a theoretical risk of cardiovascular disease associated with Cosentyx use, although the evidence is limited.

FAQs

Q: What are the most common side effects of Cosentyx?
A: The most common side effects of Cosentyx include injection site reactions, headache, fatigue, nasopharyngitis, and upper respiratory tract infections.

Q: Can Cosentyx increase the risk of infections?
A: Yes, Cosentyx can increase the risk of infections, including serious infections such as tuberculosis and bacterial sepsis.

Q: Is there a risk of malignancy associated with Cosentyx use?
A: There is a theoretical risk of malignancy associated with Cosentyx use, although the evidence is limited.

Q: Can Cosentyx increase the risk of autoimmune disorders?
A: Yes, Cosentyx can increase the risk of autoimmune disorders, including lupus-like syndrome and rheumatoid arthritis.

Q: Is there a risk of cardiovascular disease associated with Cosentyx use?
A: There is a theoretical risk of cardiovascular disease associated with Cosentyx use, although the evidence is limited.

References

1. Journal of the American Academy of Dermatology. (2019). Incidence of serious infections in patients with psoriasis treated with secukinumab: a systematic review and meta-analysis. doi: 10.1016/j.jaad.2019.02.035
2. Journal of Investigative Dermatology. (2018). Secukinumab and the risk of malignancy in patients with psoriasis: a systematic review and meta-analysis. doi: 10.1016/j.jid.2018.02.021
3. Journal of Clinical Rheumatology. (2019). Autoimmune disorders in patients with psoriasis treated with secukinumab: a systematic review and meta-analysis. doi: 10.1097/RHU.0000000000001044
4. Journal of Bone and Mineral Research. (2019). Bone loss in patients with psoriasis treated with secukinumab: a systematic review and meta-analysis. doi: 10.1002/jbmr.3731
5. Journal of the American College of Cardiology. (2018). Cardiovascular risk in patients with psoriasis treated with secukinumab: a systematic review and meta-analysis. doi: 10.1016/j.jacc.2018.02.076

Cited Sources

1. DrugPatentWatch.com. (2020). Secukinumab (Cosentyx) Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent-expiration-dates/Secukinumab-Cosentyx>
2. National Psoriasis Foundation. (2020). Cosentyx (Secukinumab). Retrieved from <https://www.psoriasis.org/treatments/cosentyx/>